Cabot (CBT) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
4 Feb, 2026Executive summary
Adjusted EPS for Q1 FY2026 was $1.53, down 13% year-over-year, with GAAP EPS at $1.37, reflecting lower EBIT in Reinforcement Materials and higher EBIT in Performance Chemicals.
Net sales for Q1 FY2026 were $849 million, down $106 million year-over-year, driven by less favorable pricing, product mix, and lower volumes in both segments, partially offset by favorable currency impacts.
Battery Materials product line delivered 39% revenue growth year-over-year, with EBITDA margins at 22% on a trailing twelve-month basis.
Signed a multi-year supply agreement with PowerCo SE, a Volkswagen subsidiary, for lithium-ion battery materials, reinforcing leadership in Battery Materials.
Returned $76 million to shareholders via dividends and share repurchases, supported by $126 million in operating cash flow.
Financial highlights
Cash flows from operations reached $126 million; discretionary free cash flow was $71 million.
Cash and cash equivalents stood at $230 million at quarter-end; liquidity position at $1.4 billion.
Capital expenditures for Q1 were $69 million; full-year CapEx expected between $200 million and $230 million.
Net debt to EBITDA stood at 1.2x as of December 31, 2025.
Free cash flow for the quarter was $57 million.
Outlook and guidance
Adjusted EPS guidance for FY2026 narrowed to $6.00–$6.50, assuming current FX, oil, and interest rates.
Reinforcement Materials volumes expected to be flat year-over-year, with some loss in Europe offset by new assets in Indonesia and Mexico.
Performance Chemicals segment anticipates low single-digit volume growth, led by battery materials and select end markets.
Continued strong free cash flow and robust balance sheet expected to support investments and shareholder returns.
Targeting an additional $30 million in cost savings in FY2026, on top of $50 million realized in FY2025.
Latest events from Cabot
- Q3 adjusted EPS up 35% year-over-year; FY2024 guidance raised on strong segment growth.CBT
Q3 20242 Feb 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.CBT
Proxy Filing27 Jan 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong ESG focus.CBT
Proxy Filing27 Jan 2026 - 31% EPS growth, $265M returned to shareholders, and 2025 EPS guidance of $7.40–$7.80.CBT
Q4 202416 Jan 2026 - FY24 adjusted EPS guidance raised to $7.00–$7.10, driven by battery, E2C, and inkjet growth.CBT
Investor Day 202412 Jan 2026 - Adjusted EPS up 13% to $1.76; net income and cash flow drive strong shareholder returns.CBT
Q1 20259 Jan 2026 - Annual meeting to vote on directors, executive pay, new incentive plan, and auditor ratification.CBT
Proxy Filing1 Dec 2025 - Key votes include director elections, executive pay, incentive plan, and auditor ratification.CBT
Proxy Filing1 Dec 2025 - Q3 FY25 Adjusted EPS was $1.90, with mixed segment results and strong cash flow.CBT
Q3 202523 Nov 2025